JLPC(SH:600513) Xin Lang Cai Jing·2026-01-16 08:49Core Viewpoint - Company Lianhuan Pharmaceutical (600513.SH) has received approval from the National Medical Products Administration for the clinical trial of its Class 2 improved new drug LH-2417, aimed at treating benign prostatic hyperplasia in men [1] Group 1: Drug Development - The drug LH-2417 is intended for the initial treatment of symptoms associated with benign prostatic hyperplasia in men [1] - The company currently has other prostate treatment drugs, including the marketed Class 1 new drug Aipulete Tablets (brand name: Chuanliu) and two Class 2 improved new drugs, LH-2103 Capsules and Rilugolix Tablets, which are in clinical trial stages [1] - As of the announcement date, the cumulative R&D investment for this project is approximately RMB 1.3678 million (unaudited) [1] Group 2: Regulatory Milestones - The approval for LH-2417 marks the company's first clinical approval obtained in 2026 [1]